Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)

PURPOSE: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin’s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kyoung Ha, Lee, Jae Hoon, Lee, Mark, Kim, Hoon-Gu, Do, Young Rok, Park, Yong, Oh, Sung Yong, Shin, Ho-Jin, Kim, Won Seog, Park, Seong Kyu, Kong, Jee Hyun, Park, Moo-Rim, Yang, Deok-Hwan, Kwak, Jae-Yong, Kang, Hye Jin, Mun, Yeung-Chul, Won, Jong-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873313/
https://www.ncbi.nlm.nih.gov/pubmed/35381164
http://dx.doi.org/10.4143/crt.2022.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873313/
https://www.ncbi.nlm.nih.gov/pubmed/35381164
http://dx.doi.org/10.4143/crt.2022.004

Ejemplares similares